Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.
Official title: Safety and Efficacy of Allogeneic Immunosuppressive CAR-DC Targeting FAP in the Treatment of Acute Myocardial Infarction With Cardiogenic Shock
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-01-20
Completion Date
2027-02-28
Last Updated
2026-02-02
Healthy Volunteers
No
Conditions
Interventions
FAP allogeneic immunosuppressive CAR-DC
Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion at the first day of shock.
Locations (1)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China